Skip to main content
. 2014 Nov 7;9:5167–5176. doi: 10.2147/IJN.S71891

Table 3.

Pharmacokinetic parameters for Val composite nanoparticles prepared by using the SAS process

Formulation AUC0–24 h (μg·hour/mL) Cmax (μg/mL) Tmax (hours)
Raw material 16.0±3.57 1.9±0.4 1.9±0.4
Val:HPMC =2:8 40.4±6.23a 6.2±0.9a 0.9±0.4
Val:HPMC:poloxamer 407 =2:7:1 73.8±14.0ad 13.6±3.5ad 0.5±0.3
Val:HPMC:Ryoto sugar ester L1695 =2:7:1 58.0±9.11a,b 9.9±1.6a,b 0.8±0.3
Val:HPMC:TPGS =2:7:1 61.2±10.7a,b 10.4±1.9a,b 0.6±0.3

Notes:

a

Indicates P<0.05 versus raw material

b

Indicates P<0.05 versus Val:HPMC =2:8

c

Indicates P<0.05 versus Val:HPMC:Ryoto sugar ester L1695 =2:7:1

d

Indicates P<0.05 versus Val:HPMC:TPGS =2:7:1. Data are expressed as the mean ± standard deviation (n=5).

Abbreviations: AUC, area under the concentration-time curve; Cmax, peak plasma concentration; HPMC, hydroxypropyl methylcellulose; SAS, supercritical antisolvent; Tmax, time to peak concentration; TPGS, D-α-Tocopheryl polyethylene glycol 1000 succinate; Val, valsartan.